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Background 
Currently, the war on Human Immunodeficiency Virus (HIV) focuses on 
prevention in the forms of condoms, abstinence, and status awareness.  However, once 
an individual is diagnosed with HIV, the focus on prevention switches to treatment.  A 
patient’s knowledge of personal HIV status, use of barrier methods during sexual 
activity, and adherence to Highly Active Antiretroviral Therapy (HAART) can help 
prevent new infections in the HIV negative population. An additional method to limit 
seroconversion and subsequent HIV infection from exposure is pre-exposure 
prophylaxis (PrEP).  Tenofovir disoproxil fumarate (TDF) is a commonly utilized PrEP 
agent; it is generally considered safe, however it is associated with renal, endocrine and 
bone toxicity1.  This paper aims to address the risks of PrEP administration in HIV 
negative patients.  
 
Epidemiology 
HIV is a worldwide epidemic.  It is the fourth leading cause of death worldwide2.  
This is a crisis that also affects the United States.  According to the Center for Disease 
Control (CDC), 1.2 million people are infected with HIV in the US, and 1 in 8 people are 
unaware of their HIV positive status.  There are 50,000 new HIV infections per year3, 
and every state in the United States of America has residents living with HIV.  North 
Carolina is one of eleven states considered to be a “high burden” state.  A high burden 
state was defined as greater than 20,000 people living with diagnosed HIV infection3.  
As of December 31, 2016, 34,187 people infected with HIV live in the state of North 
Carolina4.   
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Sixty-three percent  of new infections occur in the men who have sex with men 
(MSM) population3.  With almost two-thirds of new infections diagnosed in the MSM 
population, the majority of research, prevention, testing and treatment efforts are 
centered on the MSM population. However, there are other populations that are at risk 
and will continue to grow at alarming rates if they are continued to be overlooked 
because they are not deemed a high-risk group. Twenty-five percent of new infections 
are in the heterosexual population3.  In 2010, women accounted for two-thirds of new 
HIV infections contracted through heterosexual sex3.   Expanding prevention efforts in 
the heterosexual population, and more specifically in the female population, could 
decrease overall HIV transmissions.  
 
Pathophysiology 
The pathophysiology of HIV is complicated.  There are two types of HIV 
infections: HIV-1 and HIV-2.  HIV-2 is found primarily in West Africa2.  The majority of 
infections are HIV-1.  This paper will focus on HIV-1.   
HIV is a retrovirus that infects and kills helper (CD4) T cells and can infect other 
cells with CD4 surface proteins like macrophages2.  The loss of CD4 T lymphocytes 
results in decreased cell-mediated immunity and leads to increased susceptibility to 
opportunistic infections2.  How HIV enters a cell and replicates are key sites for 
treatment and prevention.   
HIV will enter into the cell by binding its gp120 protein to the CD4 protein on the 
cell surface.  Then the gp120 protein interacts with a second protein called a 
chemokine receptor, specifically CXRC4 or CCR5.  The entire viron consisting of 
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the nucleocapsid, RNA genome, and reverse transcriptase enters into the 
cytoplasm.  Reverse transcriptase then transcribes the virus’ RNA genome into 
double-stranded DNA which migrates to the nucleus and integrates into the host 
cell DNA mediated by the virus encoded endonuclease called integrase.  Using 
the host cell RNA polymerase, the viral mRNA is transcribed from the proviral 
DNA and translated into several large proteins.  Viral protease cleaves the Gag 
and Pol polymerase.  The Gag protein is cleaved to form the main core protein 
(p24), the matric protein (p17) and several smaller proteins.  The Pol poly protein 
is cleaved to form the reverse transcriptase, integrase and protease.  The 
immature viron forms in the cytoplasm of the host cell and then is cleaved by viral 
protease as the viron buds from the cell membrane.  The cleavage process 
results in a mature, infectious viron2. 
The viral processes of entry into the cell, reverse transcription of the viral RNA by the 
viron’s reverse transcriptase to double-stranded DNA, integrase from the virus to 
integrate the viral DNA into the host DNA, and viral protease cleaving proteins to form 
infectious virons are targets of the management of HIV infection and the prevention of 
transmission. 
The pathophysiology of HIV transmission and laboratory testing is important 
because the point of transmission is where PrEP is effective.  Transmission occurs via 
three routes: sexual contact, blood, or perinatal2.  In the perinatal period, transmission is 
from infected mother through the placenta, at birth, or via breast milk2.  The majority of 
perinatal infections occur at birth2.  However, maternal to fetal transmission is almost 
negligible if antiretroviral therapy (ART) is adhered to during pregnancy.  
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HIV infections progress in stages: early/acute stage, a middle/latent stage, and a 
late/immunodeficiency stage2 (Figure 1).  The acute phase usually occurs 2-4 weeks 
after infection2. The symptoms of fever, lethargy, sore throat, generalized 
lymphadenopathy, and maculopapular rash on the trunk, arms, and legs (sparing the 
palms and soles) can occur and then spontaneously resolve2.  During the acute 
infection phase, the virus is rapidly copied within the host and viral load is high. HIV 
infected persons may not have seroconverted during this time and may test negative.  
Seroconversion occurs when an HIV infected person will test positive for the virus.  
Although HIV antibodies such as the Anti-gp120 antibodies and the anti-p24 antibodies 
typically appear 10-14 days after infection, routine serologic testing may be falsely 
negative during this time and the virus may only be detectable by PCR2.  It is estimated 
that the majority of new infections occur from HIV positive patients who are in the early 
stages of the infection where there is a large viremia burden and they are unaware they 
are also infected.5  
The next phase of infection, is considered to be the latent phase.  Although the 
viral loads are lower than the acute phase, the virus is still replicating and destroying 
CD4 T-cells, but patients do not have any symptoms. With the destruction of CD4 T-
cells, patients become more immunocompromised and are unable to protect 
themselves from infections. 
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Without treatment, HIV will eventually progress 
to the final stage: AIDS. AIDS is defined as when the 
HIV infection has compromised the immune system 
severely, usually measured by the amount of CD4 
cells (below 200µ/L2,6) or when an opportunistic 
infection is diagnosed7.  Opportunistic infections (Table 
1) are distinguished as infections a non-
immunocompromised individual would be able to 
resolve without medical assistance.  Opportunistic 
infections and malignancy occur that can result in death with the increased destruction 
of CD4 T-cells.   
CD4 Count (in µ/L) Disease 
All HIV infected persons, regardless of CD4 count Tuberculosis (TB) 
<250 Coccidiomycosis 
<200 Pneumocystis 
<150 Histoplamosis 
<100 Toxoplasmosis 
Cryptococcus 
<50 Mycobacterium Avium 
Complex (MAC) 
Table 1 Opportunistic Infections based on CD4 counts8 
  
  
Early/Acute	Phase
Middle/Latent	Phase
Late/Immunocompromised	Phase
(AIDS)	
Figure	1	Stages	of	HIV	Infection 
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Management 
To date, there is no definitive cure for HIV. To manage HIV infections, patients 
are prescribed highly active anti-retroviral therapy otherwise known as HAART.  HAART 
utilizes 3-4 antiretroviral pharmacologic agents to work to reduce viral load, which helps 
reduce transmission, and increase the CD4 count to reduce opportunistic infections and 
AIDS related malignancies2.   
Two of the drugs used to in the HAART regimen have been proven to reduce HIV 
infection.  PrEP consists of reverse transcriptase inhibitors: tenofovir and emtricitabine.  
These drugs prevent the transcription of the viral RNA into double stranded DNA 
effectively stopping its ability to replicate.  Because of its efficacy in reducing HIV 
transmission based on the available trial results, the FDA approved an indication for the 
use of Truvada (TDF/FC) in combination with safer sex practices for PrEP to reduce the 
risk of sexually acquired HIV-1 in adults at high risk in 20129.  PrEP is widely recognized 
in the MSM population as a HIV transmission prevention tool. Daily use of PrEP 
reduces the HIV transmission by greater than 90% in the MSM population and 70% in 
the IV drug user population10.  Although long term use of HAART has some noted side 
effects such as renal function decline, bone mineral density decline and also 
gastrointestinal distress which will be reviewed later in greater detail, PrEP is deemed 
safe and effective.  
 
Costs of Care 
According to the CDC, the lifetime cost in treating one HIV positive patient was 
$367,134 (in 2009 dollars)11.  A cost model from a Schackmann et al based on 2012 
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data reported the cost of HIV infection for a person who became infected at the age of 
35 to be $326,500 with 29.5 years life expectancy12.  The majority of the cost of HIV 
treatment is for antiretroviral medications (60%), followed by chronic disease medication 
and for opportunistic infection prophylaxis and treatment medications (15%) and  for 
non-medications costs (25%)12.  It is estimated that the cost of avoiding a HIV infection 
based on current linkage and retention in HIV care is $229,800 12.  PrEP is more costly 
than other interventions such as condoms and abstinence.  However, it is another tool 
and its effectiveness should be explored in other populations.  Schackmann et al 
theorized that the costs to society of HIV infection extend well beyond the medical realm 
to include: social services, housing, patient time, lost productivity and physical and 
emotional distress to patients and their families12.    
The purpose of this review is to examine concerns with using PrEP and how to 
mitigate side effects and safely prescribe PrEP with proper monitoring and adherence to 
reduce the transmission of HIV.  
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Methods
 
Figure	2	PICO	question 
 
 An electronic search of PubMed for full text articles was performed.  The PICO 
question used for the search was: In HIV negative patients, what are the risks to 
administering PrEP to prevent HIV transmission? (Figure 2).  The terms HIV, PrEP, 
renal, liver, bone mass, gastrointestinal, and adherence were searched.  Included in the 
results were clinical trials, randomized control trials, reviews, full text articles, and 
published between the dates of 2012-2017.  Case studies were excluded.  Articles that 
focused on generic drugs, transgender drug interactions, HIV positive, drug comparison 
studies, mouse and other animal studies, hepatitis, uptake in tissue, and published in 
languages other than English were also excluded.   
  
In	HIV	Negative	
patients,	what	
are	the	risks	to	
administereing	
PrEP	to	prevent	
HIV	transmission?	
P=	HIV	
Negative	
Patients
I=	PrEP
C=	No	
Intervention
O=	Harm
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Results 
A total of forty-two articles were obtained from the search criteria.  The first 
search terms: HIV, PrEP, and Renal revealed nineteen articles.  The second set of 
search terms: HIV, PrEP, and Bone Mass revealed 15 articles, however, six articles 
were duplicated from the first search.   The third search using the terms: HIV, PrEP, and 
Liver, returned fourteen articles.  All hepatitis B specific articles were excluded as 
relevant to the topic of PrEP and reduction in transmission.  Humanized mice and mice 
only studies were also excluded. The fourth search with the terms: HIV, PrEP, and 
Gastrointestinal returned four articles with duplicates from previous searches. 
Cohort studies were evaluated using STROBE (Appendix A).  Meta-analyses and 
systematic reviews were evaluated using SORT Criteria (Appendix B).  Randomized-
control trials were evaluated using GRADE analysis (Appendix C).  
As shown below, there are challenges to administering PrEP and baseline 
assessment of laboratory values and risk must be performed.  Upon initiation of PrEP, 
various testing for pregnancy, HIV status and Hepatitis B status are necessary for 
proper use of PrEP.   Given toxicity of the medication, monitoring of renal function, and 
risk/benefit discussion on GI side-effects and BMD loss should occur between the 
provider and the patient.  
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Renal Function  
Although many patients tolerate PrEP without renal side-effects, some patients 
may experience renal toxicity.  The intracellular mechanism which induces 
nephrotoxicity is not well understood, but hypothesized to be a result of direct tubule-
cytotoxicity effects mediated through mitochondrial DNA injury13. In HIV infected 
persons, acute tubular necrosis has been demonstrated with varying degrees of 
scarring suggesting a reason for the sub-optimal reversibility in a minority of cases. 13  
However, other factors such as HIV infection itself can contribute to renal decline and 
cannot translate to the HIV negative population13.  It has been difficult to accurately 
ascertain the relationship between PrEP and renal function decline due to multiple 
studies having adherence issues. Studies that have examined a direct link between 
adherence rates and renal function have noted a renal decline associated with higher 
levels of adherence14.  The decrease in renal function associated with the use of PrEP 
has been noted to be small and usually reversible upon discontinuation of PrEP13.  
Mugwanya et al’s observational cohort study from the Partners PrEP randomized 
control trial demonstrated decline in renal function among the active limbs of the trial, 
but also showed that this decline is reversible (Figure 3).  The average FTC-TDF group 
(n=1308) enrollment eGFR was 128.8 mL/min/1.73m2 (p=0.73, CI= 95%), minimally 
dropping to an average end of treatment eGFR of 128.3 mL/min/1.73m2 (p=<0.01). 
Participants’ first post-drug follow-up eGFR averaged 130.0 mL/min/1.73m2 (p=0.80).  
Within 12 weeks of last on-study drug date, a 100% probability of >75% eGFR 
reversibility was met (p=0.37, 95% CI). In fact, this threshold was met for most 
participants at the 4- or 8- week marks post last on-study drug date13. 
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Figure 3 Data demonstrating minimal change in eGFR and reversibility to baseline adapted from the observational 
cohort study from the Partners PrEP trial13 
The TDF only group enrollment average eGFR was129.3 mL/min/1.73m2 (p=0.28, 
CI= 95%), end of treatment eGFR demonstrated a minute decrease to 129.0 
mL/min/1.73m2 (p=<0.01).  The TDF only participants’ first post-drug follow-up averaged 
eGFR 130.1 mL/min/1.73m2 (p=0.00).  Participants were also evaluated in four week 
intervals demonstrating a 100% probability of > 75% eGFR reversibility was met by 12 
weeks (p=0.49, 95% CI).  The majority of the participants in the TDF arm of the trial also 
met the threshold by last on-study drug date 4 and 8 week assessments as in the FDC-
TDF group13.  
The initial eGFR average of the placebo group enrollment was 128.6 
mL/min/1.73m2, which actually increased to 131.3  mL/min/1.73m2 (p=<0.01) at the end 
of treatment.  However, the first post-drug follow-up average decreased to eGFR 130.1 
mL/min/1.73m2 (p=0.99).  By the 12 week mark, the probability for the placebo arm to 
0
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return to a eGFR of >75% of the initial eGFR was 100%, as in the FDC-TDF and TDF 
only arms of the trial13.  This observational cohort study from Partners PrEP RCT 
successfully demonstrated a minor decrease in eGFR for the duration of the drug as 
well as reversibility of eGFR to nearly the same value.   
Likewise, as noted in an observational cohort study by Gandhi et al examined the 
long-term use of tenofovir-disoproxil-fumarate/ emtricitabine (TDF/FTC) on renal 
function, using creatinine clearance (CrCl) as a measurement, in combination with 
adherence by testing levels of TDF/FTC in hair samples. The average decline in CrCl 
for all participants over the duration of the study was −2.9% (95% CI: −2.4% to −3.4%), 
p<0.0001. Declines in CrCl were significantly greater over time in participants who 
started PrEP at older ages: −2.6% decline (95% CI: −2.4% to −3.4%) in those with 
baseline age <40 years; versus a −4.2% (95% CI: −2.8% to −5.5%) decline for 
participants with starting age 40–50 years (p<0.001 in comparison to <40 years); and 
−4.9% decline (95% CI: −3.1% to −6.8%) for participants with baseline age ≥50 years 
(p<0.001) when adjusted for baseline CrCl14. 
 There are some risk factors that have been linked to increased likelihood of renal 
function decline.  Renal function normally deteriorates in individuals as age increases. 
Older age was noted to be a risk factor for decline while receiving PrEP14. While the 
studies differed on the age ranges for data collection, the outcome of increased age 
associated with decline in renal function was consistent.   
The observational cohort study by Gandhi et all from the iPrEx OLE study also  
demonstrated that higher GFRs at the initiation of PrEP were associated with higher 
Prescribing	PrEP:	A	Guide	to	Oral	HIV	Prophylaxis	|	Alyse	J.	Moses-Lebron		
	
	 14	
rates of decline14.  There was a +3.2% (+2.1 to +4.3) increase in those participants who 
started PrEP in the lowest quartile of baseline CrCl (56–100 ml/min).  Participants in the 
2nd quartile (a CrCl of 101-113ml/min) demonstrated a −2.0% (−3.1 to −0.9) decrease.  
Participants in the 3rd quartile of CrCl (114-128ml/min) displayed a decreased of −3.6% 
(−4.7 to −2.5).  Participants in the highest quartile with a CrCl of 129-208ml/min 
revealed a −10·0% (−11·2 to −8·8), p < 0·0001 decrease14. 
Other factors associated with decreased renal function in the population which 
does not utilize PrEP such as hypertension and recent NSAID did not show an 
association with increased risk for decline in renal function during use of PrEP14. 
Diabetes was associated with a borderline increased risk of renal function decline 14. 
Current guidelines for renal function monitoring of PrEP users is to obtain eCrCL 
biannually 2,9 and PrEP should be discontinued if the CrCl falls to 60 ml/min9 or 
below.  For additional renal concerns, more frequent monitoring and additional tests 
such as urinalysis for proteinuria are recommended.  Using clinical judgement to involve 
a nephrologist or evaluate for other renal concerns in patients with steadily declining 
GFRs, but still above the 60 mL/min withdrawal limit is also encouraged 9. 
 
Bone Mineral Density and Management  
 Osteoporosis and fracture risk is increased in HIV-infected adults, and anti-
retroviral therapy is associated with rapid bone loss15.  PrEP users have a low absolute 
risk of fracture15, but concern with bone mineral density loss in an otherwise healthy 
population is problematic.  A sub-study of iPrEX, a randomized double-blind, placebo-
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controlled trial of FTC/TDF PrEP demonstrated net differences in bone mineral density 
(BMD) were modest but consistently below zero, indicating greater BMD loss in the 
FTC/TDF group. Participants had a baseline BMD evaluation and then were followed in 
24 week increments.  Participants in the FDC/TDF group were found to have a change 
of −0.91% [95% CI, −1.44% to −.38%], P = .001 in BMD at week 24. After week 24, 
further net changes averaged −0.12% [95% CI −.36% to .12%] for each additional 24-
week interval and were not statistically significant (P = .28)16. 
Bone mineral density decrease is another concern regarding administering PrEP 
to healthy individuals. Currently, PrEP is widely used in the younger MSM population.  
While males are not considered to be a high-risk group for osteopenia and 
osteoporosis, administering PrEP to a younger population with some users who have 
not reached complete bone mineral density maturity was done so with apprehension 
due to a theoretical risk to bone health.  Multiple studies have demonstrated that the 
bone loss with use of TDF in PrEP is reversible 15–18. Mulligan et all found that loss of 
BMD reversed after stopping PrEP (Figure 4). Reversibility was more significant in the 
spine. 
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Figure 4: Graphical representation of data adapted from iPrEX sub-study demonstrating BMD increasing after 
cessation of PrEP use. Participants in this study were followed 24 weeks after cessation of PrEP use. 
Additionally, bone mineral density recovery was the greatest in the < 25 years old 
population who had not reached peak bone mass yet after PrEP discontinuation15.  HIV 
infection alone can be a cause for bone mineral density loss.  Reassuringly, bone loss 
among highly adherent PrEP users was still less than that observed after starting 
combination ART for HIV infection16 . The exact mechanism for bone mineral density 
loss in HIV uninfected patients is unclear.  Renal tubular damage with phosphate 
wasting may be a key factor in the bone toxicity associated with TDF1.    
Evidence is divided as to adjunct calcium therapies to combat the effects of bone 
mineral density loss. According to Kasonde et all,  some clinical trials found a positive 
effect of calcium supplementation on the bone mineral density in children and 
adolescents19.   This data could suggest that calcium supplementation in PrEP users 
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could be beneficial to reduce the decrease in bone mineral density in PrEP users.  
However, in a meta-analysis of randomized placebo controlled trials of calcium 
supplementation in healthy children not on PrEP, there was no effect of calcium 
supplementation on bone mineral density at the femoral neck or at the lumbar spine at 
the end of trials19.  For participants in the TDF2 sub-study placed on calcium 
supplements for low BMD at baseline, there was no significant difference from the 
original model after controlling for supplementation19. 
Another intervention to mitigate effects on bone mineral density is to remain on 
PrEP during high risk periods of contracting HIV and off of PrEP when the risk of 
acquiring HIV are low15 .  Although with the previously found reversibility of bone 
mineral density loss upon discontinuation of PrEP, use of a cycling regimen warrants 
more thorough investigation to the possible effects on bone mineral density.  This 
method would also need focused practitioners to assess the HIV acquisition risk and 
enable and educate participants to recognize their specific risk.  With adherence being 
an essential component of PrEP success, a closer examination to cycling regimens and 
social factors needs further investigation.   
Other factors can decrease BMD and should be considered when prescribing 
PrEP.  Although the majority of new heterosexual infections occur in women, they are a 
commonly underrepresented population in regards to HIV prophylaxis. With regards to 
bone health, women have unique factors apart from their male counterparts to consider. 
Estrogen and its role in BMD as well as contraception cannot be discounted.  The TDF2 
sub-study demonstrated a positive effect of oral contraception and BMD in women of all 
ages in the study, while a loss of BMD was associated with the use of depo-
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medroxyprogesterone acetate (DMPA)19.  A randomized control trial examining effects 
of TDF on bone in HIV negative women in sub-Saharan Africa who may receive PrEP 
for several years during young adulthood and who may also may be concurrently 
impacted by other factors affecting bone density including contraception, pregnancy, 
and lactation demonstrated a decrease in bone mineral density during PrEP usage and 
also an increase in BMD at both the spine and the hip when stopping therapy18.  This 
study demonstrated the reversibility of PrEP associated bone mineral density decrease 
which is similar to the results of other randomized control trials with male participants.  
Taking into account the type of contraception was a strong point of this study.  Fifty-two 
percent of participants reported a history of DMPA use18.  DMPA alone has also been 
associated with bone mineral density loss that is reversible when stopping therapy.    
There is well documented evidence of reversibility of the effects of PrEP on bone 
mineral density.  There are no guidelines for baseline DEXA scans or other bone 
mineral density testing prior to initiating PrEP or during therapy9.  The recommendation 
is that any person being considered for PrEP who has a history of pathologic or fragility 
bone fractures or who has significant risk factors for osteoporosis should be referred for 
appropriate consultation and management 9. 
 
Adherence  
Adherence has proven to be a prevalent issue during PrEP trials. The iPrEX trial 
demonstrated that participants with detectable levels of PrEP had a reduction in 
transmission of HIV-120. The relative risk (RR) of HIV-1 acquisition was estimated to be 
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reduced by 92% (95% CI, p<0.001) among participants with detectable levels of 
TDF/FTC when compared with participants without detectable levels20.  However, in the 
iPrEX trial, drug resistant virus developed in 2 people with unrecognized acute HIV 
infections at enrollment and for whom had TDF/FTC dispensed 9. This finding has 
increased concern that inconsistent PrEP users or those with decreased adherence 
could be at risk for drug-resistant HIV infection. Adherence is an important part of 
implementing PrEP as a successful intervention.   
Studies that have revealed PrEP as an ineffectual tool in HIV prevention have 
been plagued by adherence issues.   The study by Damme et all could not determine 
the effectiveness of PrEP among women due to low adherence levels21.  Although self-
reports and pill counts of participants in the PrEP trial in African women expressed high 
adherence, drug-level testing of plasma levels of TDF/FTC revealed a different picture.  
A target drug-level of 10ng per milliliter was utilized for adherence demonstrating TDF 
had been taken within the previous 48 hours21.  Among women with seroconversion in 
the TDF–FTC group, the target plasma level of tenofovir (≥10 ng per milliliter) was 
identified in 7 of 27 women (26%) at the beginning of the infection window (excluding 6 
women for whom the window started at enrollment), in 7 of 33 (21%) at the end of the 
window, and in 4 of 27 (15%) at both visits21.  Further concerns of adherence were 
validated in the PROUD study, when the incidents of post-enrollment HIV-1 infection in 
the arm of the study that received TDF/FTC immediately occurred in individuals who 
seemed to have suboptimal adherence20.  Low adherence levels in the Preexposure 
Prophylaxis Initiative study involving men who have sex with men in which tenofovir was 
detected in 44% of the uninfected controls suggested that imperfect use is more 
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forgiving in rectal HIV exposure than with vaginal exposure potentially due to the 
differences in active metabolites in the rectal and vaginal tissues after oral 
administration21.  
The majority of new HIV infections are spread via vaginal and anal sexual 
intercourse22 as opposed to IV drug use.  With HIV infections growing rapidly among the 
heterosexual female population, differences in the tissue concentrations of PrEP raises 
concern regarding the effectiveness of PrEP is its use in women.  There are differences 
in the pharmacodynamics of PrEP in vaginal tissue and anal tissue.  A recent study 
from Cottrell et al demonstrated median dose-adjusted AUC0–48h for TFV and TFVdp 
were 10–45 times higher in colorectal tissue (38.5 µg*hr*g−1 and 2046.5 pmol*hr*g−1, 
respectively), compared with female genital tract (FGT) tissue (0.83 µg*hr*g−1 and 188 
pmol*hr*g−1, respectively)22.  Although median dose-adjusted FTC AUC0–48h was higher 
in colorectal tissue (222.3 µg*hr*g−1) than FGT tissue (17.6 µg*hr*g−1), FTCtp values 
were 140 times higher in FGT tissue (15 094.3 pmol*hr*g−1) than colorectal tissue 
(108.2 pmol*hr*g−1)22. In colorectal tissue, the maximal proportion of the population 
(100%) achieved target exposure for efficacy after 3 daily doses of the fixed-dose 
combination.  In FGT tissue, the maximal proportion of the population (99%) achieved 
target exposure over the entire dosing interval after 3 daily doses of the fixed-dose 
combination. In colorectal tissue, dosing twice per week with the fixed-dose combination 
achieved target exposure in >95% of the population while in FGT tissue, this dosing 
achieved target exposure in 65% of the population22.  The evidence from the 
pharmacodynamics study suggests that people at risk of HIV acquisition from vaginal 
intercourse can still successfully utilize PrEP, though due to pharmacodynamics they 
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need to be more adherent and may need more doses than those at risk of HIV infection 
from anal intercourse to achieve the same level of protection from seroconversion.  
Side effects can be an additional factor that affects adherence and should be 
discussed with patients with a plan to mitigate side effects9. Side effects are uncommon, 
and usually resolve within the first month of taking PrEP and termed “start-up 
syndrome”9.  Common side effects are headache9, nausea9,23, vomiting23, diarrhea23, 
and flatulence9 and can be mitigated with over-the-counter medicines9.  
 
Implementation Techniques 
Previously, PrEP was only available in clinical trials and use was limited by the 
duration of the study, however now it is increasingly being provided in a variety of 
clinical settings24.  In order to successfully implement the delivery of PrEP to patients at 
risk for HIV infection, there must be a program in place to access and monitor patients. 
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Marcus et all described a continuum of care model for PrEP delivery24 (Figure 5).
 
Figure 5 The Continuum of Care for Successful PrEP Use as described by Marcus et all 
   
The first step is identification of individuals at risk for HIV infection24.  Based on 
CDC guidelines, several populations can benefit from PrEP.  The first step in assessing 
a need for PrEP is establishing the presence of risk factors in the patient.  According to 
the CDC, risk factors for HIV infection are divided among three groups: MSM, 
Heterosexual Women and Men, and Injection Drug Users (IDU) (Figure 6).9  The risk 
factors for the MSM population include: HIV positive sexual partner, recent bacterial 
STI, high number of sexual partners, history of inconsistent or no condom use, and 
commercial sex work9.  The risk factors for the heterosexual women and men include: 
HIV positive sexual partner, recent bacterial STI, high number of sexual partners, 
history of inconsistent or no condom use, commercial sex work, and located in a high-
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prevalence area or network9.  Risk factors for IDU are: HIV positive injecting partner, 
sharing injection equipment, and recent drug treatment with current injection behaviors9. 
 
Figure 6 Persons at risk for HIV infection according to CDC guidelines9 
 The second step is linkage to individuals at risk for HIV infection to a PrEP 
provider and site24.  Linkage can also accompany the identification step.  Marcus et al 
evaluated PrEP implementation models including: Health Maintenance Organization 
(HMO) setting, STI clinic setting, and Primary Care setting24.  In an HMO setting, the 
majority of referrals are initiated by patients, however in a STI clinic setting it was 
clinicians who identified a risk and offered PrEP to patients24.  In a primary care setting, 
PrEP was offered to patients who specifically requested it from their providers and those 
who are identified as having an elevated risk for HIV infection during a sexual risk 
assessment 24.   
 Initiation of PrEP is the third step described by Marcus et al.  Initiation 
includes not only baseline laboratory tests such as HIV, Hepatitis B, and creatinine, but 
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also a mechanism to pay for PrEP and the continued care needed for ongoing use of 
PrEP24.  
According to the CDC, clinicians should document a HIV negative test within a 
week prior to initiation or re-initiation of PrEP medications at a minimum 9.  HIV testing 
can be performed by HIV EIA (enzyme-linked immunoassay) or performing a rapid, 
point-of-care, FDA-approved finger stick blood test9.  Oral rapid tests can be less 
sensitive than blood tests are should be used to screen for HIV infection in the context 
of administering PrEP9.  Preliminary positive HIV antibody tests must be confirmed by 
Western blot or IFA (immunofluorescence assay) and viral load and CD4 lymphocyte 
tests9.  The CDC recommends baseline renal function testing to ensure patients with a 
CrCl less than 60 mL/min are not prescribed PrEP with TDF/FTC 9.  The CDC also 
recommends hepatitis serology for Hepatitis B (HBV) and Hepatitis C (HCV)9.  
Education about side effects, possible toxicities, and adherence is part of the initiation of 
PrEP24.  Currently, the medications that are approved for PrEP are TDF and FTC (Table 
2)9.  FTC should not be used alone and only in conjunction with TDF9. Additionally, the 
only dosing schedule approved is daily dosing9.   
Generic Name Trade Name Dose Frequency Common Side 
Effects 
Tenofovir 
disoproxil 
fumarate* 
(TDF) 
Viread 300mg Once a day Nausea, 
flatulence 
Emtricitabine** 
(FTC) 
Emtriva 200mg Once a day Rash, 
headache 
TDF +FTC Truvada 300mg/200mg Once a day  
Table 2 Recommended Oral PrEP Medications according to the CDC9 
* TDF alone has proven effective in trials with IDU and heterosexually active men and 
women so it may be considered as a regiment in those populations 
**Emitricitabine (FTC) should not be used alone for PrEP.  
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There are several financial assistance programs available to patients if they 
qualify based on their income level, geographic location, and insurance status.  Gilead 
Sciences offers PrEP to US residents who earn <500% of the federal poverty level at no 
cost24,25.  There are additional programs for New York and Washington state 
residents25.  Some insurance will also cover some of the costs of PrEP.  
 
 The final step of PrEP implementation is engagement24.  This step is maintaining 
adherence and completing laboratory testing.  Engagement requires follow-up with a 
PrEP provider for laboratory testing such as HIV testing, STI testing, and renal function 
testing (Figure 7)9 . 
	
Figure 7 Clinical Follow-Up and Monitoring Schedule According to the CDC 
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 Based on the type of PrEP implementation program, some of the visits may be 
laboratory visits and contact may be achieved by communication within the electronic 
medical record (EMR)24.    
  
Discussion 
While lifestyle modifications are first line in HIV prophylaxis, PrEP is a valuable 
tool in HIV infection prevention.  As with other chronic diseases such as hypertension 
and diabetes, lifestyle modifications while extremely effective, are difficult for patients to 
implement and maintain.  PrEP, in addition to lifestyle modifications, has been proven 
as a successful regimen.  
However, as highlighted in the results section, PrEP is not without side effects. 
The gastrointestinal side effects that are most noticeable to patients could affect 
adherence.  Discussions with patients and techniques to combat unpleasant side effects 
can help increase adherence.  Decreased adherence affects the efficacy of PrEP.  
Baseline renal insufficiency and decreased bone mineral density can affect a patient’s 
eligibility for oral PrEP.  With reversibility of both decreased renal function and bone 
mineral density demonstrated in many trials, PrEP has shown to be relatively well-
tolerated and safe.   
While there are many studies examining PrEP use in the MSM population in the 
United States, and heterosexual males and females in endemic areas such as Africa, 
more studies on implementing PrEP programs for heterosexual males and females in 
the United States are needed.  Heterosexual males and females, females specifically as 
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they account for two-thirds of the new HIV infections in heterosexuals in the United 
States, are a potentially missed population that would greatly benefit from this 
intervention.  
Implementing a PrEP program can assist providers to discuss sexual health, 
drug use, and HIV infection with patients.  Many times, HIV is the “elephant in the 
room”.  Discussing risk and life style modifications can also help reduce the stigma that 
plagues detection of this disease.  Prior to initiating PrEP, testing for HVB, HVC, and 
HIV as well as other STIs is necessary.  To determine if someone is a candidate for 
PrEP renal function testing is also necessary as PrEP can only be administered if CrCl 
is greater than 60mL/min.  Regardless of where the PrEP program is implemented, a 
primary care setting or subspecialty clinic, close monitoring and follow-up is needed to 
ensure continued safety, adherence, and need for PrEP as a tool to prevent HIV 
infection.   
Administering PrEP on a large scale would be costly, but there are programs to 
assist with the financial burden for some eligible patients.  The financial and social costs 
of treating HIV infection are also high.  With the implementation of PrEP programs by 
providers, building greater rapport between providers and patients by discussing risk, 
and patients learning and practicing lifestyle modifications, can decrease the stigma of 
HIV infection along with seroconversions of this disease.   
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Conclusion 
 Evaluating a patient’s risk for acquiring HIV infection is the first step to initiating 
PrEP.  PrEP is generally well tolerated.  With appropriate monitoring of HIV status, renal 
function, other STIs, and medication interactions, PrEP is a safe and effective method to 
prevent HIV infections in those at risk.  Providers should become familiar with assessing 
their patients’ risk of HIV infection and providing resources for patients to obtain PrEP.  
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Appendix	A	STROBE	Analysis 
Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With 
Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected 
Adolescent Boys and Young Men for HIV Preexposure Prophylaxis by Havens et al 
STROBE Score: 20 
 
Title and Abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract [not present] 
(b) Provide in the abstract an informative and 
balanced summary of what was done and 
what was found [Pg. 317] 
Introduction   
Background/rationale 2 Explain the scientific background and rationale 
for the investigation being reported [Pg. 317-318] 
Objectives 3 State specific objectives, including any pre-
specified hypotheses [Pg. 318] 
Methods   
Study design 4 Present key elements of study design early in 
paper [Pg. 318] 
Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, exposure, 
follow-up, and data collection [Pg. 318] 
Participants 6 (a) Cohort study: give the eligibility criteria, 
and the sources and methods of selection 
of participants.  Describe methods of 
follow-up [Pg. 318] 
Case-Control Study:  Give the eligibility 
criteria, and the sources and methods of 
case ascertainment and control selection.  
Give the rationale for the choice of cases 
and controls  
Cross-Sectional study: Give the eligibility 
criteria, and the sources and methods of 
selection of participants 
(b) Cohort Study: For matched studies, give 
matching criteria and the number of 
controls per case [Pg. 318] 
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers.  Give diagnostic criteria, if applicable 
[Pg. 318] 
Data 
Sources/measurement* 
8 For each variable of interest, give sources of data 
and details of methods assessment.  Describe 
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comparability of assessment methods if there is 
more than one group [Pg. 318] 
Bias 9 Describe any efforts to address potential sources 
of bias [Pg. 318-319] 
Study Size 10 Explain how the study size was arrived at [Pg. 
319] 
Quantitative variables 11 Explain how quantitative variables were handled 
in the analyses.  If applicable, describe which 
groupings were chosen and why [Pg. 318-319] 
Statistical Methods 12 (a) Describe all statistical methods, including 
those used to control for confounding [Pg. 
318-319] 
(b) Describe any methods used to examine 
subgroups and interactions 
(c) Explain how missing data were addressed 
[Pg. 319] 
(d) Cohort study:  If applicable, explain how 
loss to follow up was addressed [Pg. 319] 
Case-Controlled study: If applicable, 
explain how matching cases and controls 
was addressed 
Cross-sectional study: If applicable, 
describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analysis [Pg. 319] 
Results   
Participants 13* (a) Report the numbers of individuals at each 
stage of the study- e.g. numbers 
potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, 
completing follow-up and analyzed [Pg. 
319] 
(b) Give reasons for nonparticipation at each 
stage [Pg. 319] 
(c) Consider use of a flow diagram [not 
present] 
Descriptive Data 14* (a) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
information on exposures and potential 
confounders [Pg. 319- 320] 
(b) Indicate the number of participants with 
missing data for each variable of interest 
[Pg. 319] 
(c) Cohort study:  Summarize follow-up time- 
e.g. average and total amount [Pg. 320] 
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Outcome Data 15* Cohort study: Report numbers of outcome events 
or summary measures over time [Pg. 322] 
Case control study: Report numbers in each 
exposure category or summary measures of 
exposure  
Cross-sectional study: Report numbers of 
outcome events or summary measures 
Main Results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g. 95% CI).  Make 
clear which confounders were adjusted for 
and why they were included [Pg. 322] 
(b) Report category boundaries when 
continuous variables were analyzed [Pg. 
321] 
(c) If Relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period 
Other Analyses 17 Report other analyses done- e.g. analyses of 
subgroups and interactions and sensitivity 
analyses [Pg. 321-322] 
Discussion   
Key results 18 Summarize key results with reference to study 
objectives [Pg. 323] 
Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or imprecision.  
Discuss both direction and magnitude of any 
potential bias [Pg. 323] 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence [Pg. 324] 
Generalizability 21 Discuss the generalizability (external validity) of 
the study results. [Pg. 324] 
Other Information   
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, of 
the original study on which the present article is 
based. [Pg. 324] 
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The Lifetime Medical Cost Savings From Preventing HIV in the United States by Schackman 
et al 
STROBE Score: 18 
 
Title and Abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract [not present] 
(b) Provide in the abstract an informative and 
balanced summary of what was done and 
what was found [Pg. 2] 
Introduction   
Background/rationale 2 Explain the scientific background and rationale 
for the investigation being reported [Pg. 2] 
Objectives 3 State specific objectives, including any pre-
specified hypotheses [Pg. 2] 
Methods   
Study design 4 Present key elements of study design early in 
paper [Pg. 3] 
Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, exposure, 
follow-up, and data collection [Pg. 5] 
Participants 6 (a) Cohort study: give the eligibility criteria, 
and the sources and methods of selection 
of participants.  Describe methods of 
follow-up  
Case-Control Study:  Give the eligibility 
criteria, and the sources and methods of 
case ascertainment and control selection.  
Give the rationale for the choice of cases 
and controls  
Cross-Sectional study: Give the eligibility 
criteria, and the sources and methods of 
selection of participants 
(b) Cohort Study: For matched studies, give 
matching criteria and the number of 
controls per case [not present] 
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers.  Give diagnostic criteria, if applicable 
[Pg. 4] 
Data 
Sources/measurement* 
8 For each variable of interest, give sources of data 
and details of methods assessment.  Describe 
comparability of assessment methods if there is 
more than one group [Pg. 4] 
Bias 9 Describe any efforts to address potential sources 
of bias [Pg. 5] 
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Study Size 10 Explain how the study size was arrived at [Pg. 5] 
Quantitative variables 11 Explain how quantitative variables were handled 
in the analyses.  If applicable, describe which 
groupings were chosen and why [Pg. 5] 
Statistical Methods 12 (a) Describe all statistical methods, including 
those used to control for confounding [Pg. 
5] 
(b) Describe any methods used to examine 
subgroups and interactions 
(c) Explain how missing data were addressed 
[Pg. 5] 
(d) Cohort study:  If applicable, explain how 
loss to follow up was addressed  
Case-Controlled study: If applicable, 
explain how matching cases and controls 
was addressed 
Cross-sectional study: If applicable, 
describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analysis [Pg. 5-6] 
Results   
Participants 13* (a) Report the numbers of individuals at each 
stage of the study- e.g. numbers 
potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, 
completing follow-up and analyzed [not 
present] 
(b) Give reasons for nonparticipation at each 
stage [not present] 
(c) Consider use of a flow diagram [not 
present] 
Descriptive Data 14* (a) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
information on exposures and potential 
confounders [Pg. 319- 320] 
(b) Indicate the number of participants with 
missing data for each variable of interest 
[Pg. 319] 
(c) Cohort study:  Summarize follow-up time- 
e.g. average and total amount [Pg. 320] 
Outcome Data 15* Cohort study: Report numbers of outcome events 
or summary measures over time [Pg. 5] 
Case control study: Report numbers in each 
exposure category or summary measures of 
exposure  
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Cross-sectional study: Report numbers of 
outcome events or summary measures 
Main Results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g. 95% CI).  Make 
clear which confounders were adjusted for 
and why they were included [Pg. 6,7 and 
17] 
(b) Report category boundaries when 
continuous variables were analyzed 
(c) If Relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period 
Other Analyses 17 Report other analyses done- e.g. analyses of 
subgroups and interactions and sensitivity 
analyses [Pg. 5 and 7] 
Discussion   
Key results 18 Summarize key results with reference to study 
objectives [Pg. 8] 
Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or imprecision.  
Discuss both direction and magnitude of any 
potential bias [Pg. 8-9] 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence [Pg. 9] 
Generalizability 21 Discuss the generalizability (external validity) of 
the study results. [Pg. 9] 
Other Information   
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, of 
the original study on which the present article is 
based. [not present] 
 
Reversibility of Glomerular Renal Function Decline in HIV Uninfected Men and Women 
Discontinuing Emtricitabine- Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis 
by Mugwanya et al 
STROBE Score:18 
 
Title and Abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract [not present] 
(b) Provide in the abstract an informative and 
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balanced summary of what was done and 
what was found [Pg. 1] 
Introduction   
Background/rationale 2 Explain the scientific background and rationale 
for the investigation being reported [Pg. 2] 
Objectives 3 State specific objectives, including any pre-
specified hypotheses [Pg. 2] 
Methods   
Study design 4 Present key elements of study design early in 
paper [Pg. 2] 
Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, exposure, 
follow-up, and data collection [Pg. 2] 
Participants 6 (a) Cohort study: give the eligibility criteria, 
and the sources and methods of selection 
of participants.  Describe methods of 
follow-up [Pg. 3] 
Case-Control Study:  Give the eligibility 
criteria, and the sources and methods of 
case ascertainment and control selection.  
Give the rationale for the choice of cases 
and controls  
Cross-Sectional study: Give the eligibility 
criteria, and the sources and methods of 
selection of participants 
(b) Cohort Study: For matched studies, give 
matching criteria and the number of 
controls per case [Pg. 3-4] 
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers.  Give diagnostic criteria, if applicable 
[Pg. 4] 
Data 
Sources/measurement* 
8 For each variable of interest, give sources of data 
and details of methods assessment.  Describe 
comparability of assessment methods if there is 
more than one group [Pg. 3-4] 
Bias 9 Describe any efforts to address potential sources 
of bias [not present] 
Study Size 10 Explain how the study size was arrived at [Pg.3] 
Quantitative variables 11 Explain how quantitative variables were handled 
in the analyses.  If applicable, describe which 
groupings were chosen and why [Pg. 3] 
Statistical Methods 12 (a) Describe all statistical methods, including 
those used to control for confounding [Pg. 
4] 
(b) Describe any methods used to examine 
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subgroups and interactions [not present] 
(c) Explain how missing data were addressed 
[Pg. 5 
(d) Cohort study:  If applicable, explain how 
loss to follow up was addressed  
Case-Controlled study: If applicable, 
explain how matching cases and controls 
was addressed 
Cross-sectional study: If applicable, 
describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analysis [Pg. 4] 
Results   
Participants 13* (a) Report the numbers of individuals at each 
stage of the study- e.g. numbers 
potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, 
completing follow-up and analyzed [Pg. 5] 
(b) Give reasons for nonparticipation at each 
stage [Pg. 5] 
(c) Consider use of a flow diagram [not 
present] 
Descriptive Data 14* (a) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
information on exposures and potential 
confounders [Pg. 12] 
(b) Indicate the number of participants with 
missing data for each variable of interest 
[Pg. 5] 
(c) Cohort study:  Summarize follow-up time- 
e.g. average and total amount [Pg.4, 5, 
and 13 ] 
Outcome Data 15* Cohort study: Report numbers of outcome events 
or summary measures over time [Pg. 5, 6, and 
13] 
Case control study: Report numbers in each 
exposure category or summary measures of 
exposure  
Cross-sectional study: Report numbers of 
outcome events or summary measures 
Main Results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g. 95% CI).  Make 
clear which confounders were adjusted for 
and why they were included [Pg. 13] 
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(b) Report category boundaries when 
continuous variables were analyzed [Pg. 
13] 
(c) If Relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period 
Other Analyses 17 Report other analyses done- e.g. analyses of 
subgroups and interactions and sensitivity 
analyses [Pg. 6 and 12] 
Discussion   
Key results 18 Summarize key results with reference to study 
objectives [Pg. 7] 
Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or imprecision.  
Discuss both direction and magnitude of any 
potential bias [Pg. 8] 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence [Pg. 7-8] 
Generalizability 21 Discuss the generalizability (external validity) of 
the study results. [Pg. 7-8] 
Other Information   
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, of 
the original study on which the present article is 
based. [Pg. 8] 
 
 
 
 
 
HHS Public Access: Age, baseline kidney function, and medication exposure are associated 
with declines in creatinine clearance on PrEP: an observational cohort study by Gandhi 
et al 
STROBE Score: 22 
 
Title and Abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract [Pg.1] 
(b) Provide in the abstract an informative and 
balanced summary of what was done and 
what was found [Pg. 2] 
Introduction   
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Background/rationale 2 Explain the scientific background and rationale 
for the investigation being reported [Pg. 2] 
Objectives 3 State specific objectives, including any pre-
specified hypotheses [Pg. 3] 
Methods   
Study design 4 Present key elements of study design early in 
paper [Pg. 4] 
Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, exposure, 
follow-up, and data collection [Pg. 4] 
Participants 6 (a) Cohort study: give the eligibility criteria, 
and the sources and methods of selection 
of participants.  Describe methods of 
follow-up [Pg. 4] 
Case-Control Study:  Give the eligibility 
criteria, and the sources and methods of 
case ascertainment and control selection.  
Give the rationale for the choice of cases 
and controls  
Cross-Sectional study: Give the eligibility 
criteria, and the sources and methods of 
selection of participants 
(b) Cohort Study: For matched studies, give 
matching criteria and the number of 
controls per case [pg. 16-18] 
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers.  Give diagnostic criteria, if applicable 
[Pg. 4-5] 
Data 
Sources/measurement* 
8 For each variable of interest, give sources of data 
and details of methods assessment.  Describe 
comparability of assessment methods if there is 
more than one group [Pg. 4-5] 
Bias 9 Describe any efforts to address potential sources 
of bias [Pg. 4 and 6] 
Study Size 10 Explain how the study size was arrived at [Pg. 4] 
Quantitative variables 11 Explain how quantitative variables were handled 
in the analyses.  If applicable, describe which 
groupings were chosen and why [Pg. 4] 
Statistical Methods 12 (a) Describe all statistical methods, including 
those used to control for confounding [Pg. 
4-5] 
(b) Describe any methods used to examine 
subgroups and interactions [Pg. 5] 
(c) Explain how missing data were addressed 
[Pg. 5] 
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(d) Cohort study:  If applicable, explain how 
loss to follow up was addressed  
Case-Controlled study: If applicable, 
explain how matching cases and controls 
was addressed 
Cross-sectional study: If applicable, 
describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analysis [Pg. 5-6] 
Results   
Participants 13* (a) Report the numbers of individuals at each 
stage of the study- e.g. numbers 
potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, 
completing follow-up and analyzed [Pg. 5-
6] 
(b) Give reasons for nonparticipation at each 
stage [Pg. 6] 
(c) Consider use of a flow diagram [not 
present] 
Descriptive Data 14* (a) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
information on exposures and potential 
confounders [Pg. 16-18] 
(b) Indicate the number of participants with 
missing data for each variable of interest 
[Pg. 5] 
(c) Cohort study:  Summarize follow-up time- 
e.g. average and total amount [Pg. 5-6] 
Outcome Data 15* Cohort study: Report numbers of outcome events 
or summary measures over time [Pg.16-18 ] 
Case control study: Report numbers in each 
exposure category or summary measures of 
exposure  
Cross-sectional study: Report numbers of 
outcome events or summary measures 
Main Results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g. 95% CI).  Make 
clear which confounders were adjusted for 
and why they were included [Pg.5, 6, 16-
18] 
(b) Report category boundaries when 
continuous variables were analyzed [Pg. 
16-18] 
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(c) If Relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period [Pg. 16-18] 
Other Analyses 17 Report other analyses done- e.g. analyses of 
subgroups and interactions and sensitivity 
analyses [Pg. 4-5] 
Discussion   
Key results 18 Summarize key results with reference to study 
objectives [Pg. 7-9] 
Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or imprecision.  
Discuss both direction and magnitude of any 
potential bias [Pg. 8] 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence [Pg. 8] 
Generalizability 21 Discuss the generalizability (external validity) of 
the study results. [Pg. 9] 
Other Information   
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, of 
the original study on which the present article is 
based. [Pg. 5] 
 
 
 
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a 
Randomized, Double-Blind, Placebo Controlled Trial by Mulligan et al 
STROBE Score: 21 
 
Title and Abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract [Pg.572] 
bb) Provide in the abstract an informative and 
balanced summary of what was done and 
what was found [Pg. 572] 
Introduction   
Background/rationale 2 Explain the scientific background and rationale 
for the investigation being reported [Pg. 572-573] 
Objectives 3 State specific objectives, including any pre-
specified hypotheses [Pg. 573] 
Methods   
Study design 4 Present key elements of study design early in 
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paper [Pg. 573] 
Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, exposure, 
follow-up, and data collection [Pg. 573] 
Participants 6 (a) Cohort study: give the eligibility criteria, 
and the sources and methods of selection 
of participants.  Describe methods of 
follow-up [Pg. 573] 
Case-Control Study:  Give the eligibility 
criteria, and the sources and methods of 
case ascertainment and control selection.  
Give the rationale for the choice of cases 
and controls  
Cross-Sectional study: Give the eligibility 
criteria, and the sources and methods of 
selection of participants 
(b) Cohort Study: For matched studies, give 
matching criteria and the number of 
controls per case  
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers.  Give diagnostic criteria, if applicable 
[Pg. 573] 
Data 
Sources/measurement* 
8 For each variable of interest, give sources of data 
and details of methods assessment.  Describe 
comparability of assessment methods if there is 
more than one group [Pg. 573] 
Bias 9 Describe any efforts to address potential sources 
of bias [Pg. 573] 
Study Size 10 Explain how the study size was arrived at [Pg. 
573] 
Quantitative variables 11 Explain how quantitative variables were handled 
in the analyses.  If applicable, describe which 
groupings were chosen and why [Pg. 573] 
Statistical Methods 12 (a) Describe all statistical methods, including 
those used to control for confounding [Pg. 
573] 
(b) Describe any methods used to examine 
subgroups and interactions [Pg. 573] 
(c) Explain how missing data were addressed 
[Pg. 573] 
(d) Cohort study:  If applicable, explain how 
loss to follow up was addressed  
Case-Controlled study: If applicable, 
explain how matching cases and controls 
was addressed 
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Cross-sectional study: If applicable, 
describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analysis [not 
present] 
Results   
Participants 13* (a) Report the numbers of individuals at each 
stage of the study- e.g. numbers 
potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, 
completing follow-up and analyzed [Pg. 
574] 
(b) Give reasons for nonparticipation at each 
stage [Pg. 574] 
(c) Consider use of a flow diagram [not 
present] 
Descriptive Data 14* (a) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
information on exposures and potential 
confounders [Pg. 574] 
(b) Indicate the number of participants with 
missing data for each variable of interest 
[Pg. 564] 
(c) Cohort study:  Summarize follow-up time- 
e.g. average and total amount [Pg. 574-
576] 
Outcome Data 15* Cohort study: Report numbers of outcome events 
or summary measures over time [Pg.577] 
Case control study: Report numbers in each 
exposure category or summary measures of 
exposure  
Cross-sectional study: Report numbers of 
outcome events or summary measures 
Main Results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g. 95% CI).  Make 
clear which confounders were adjusted for 
and why they were included [Pg. 574-576] 
(b) Report category boundaries when 
continuous variables were analyzed [Pg. 
574-576] 
(c) If Relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period  
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Other Analyses 17 Report other analyses done- e.g. analyses of 
subgroups and interactions and sensitivity 
analyses [Pg. 574-575] 
Discussion   
Key results 18 Summarize key results with reference to study 
objectives [Pg. 577] 
Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or imprecision.  
Discuss both direction and magnitude of any 
potential bias [Pg. 578] 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence [Pg. 578] 
Generalizability 21 Discuss the generalizability (external validity) of 
the study results. [Pg. 578] 
Other Information   
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, of 
the original study on which the present article is 
based. [Pg. 578-579] 
 
Recovery of Bone Mineral Density Following Discontinuation of Tenofovir-Based HIV Pre-
Exposure Prophylaxis by Glidden et al 
STROBE Score: 18 
 
Title and Abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract [Pg.2] 
(b) Provide in the abstract an informative and 
balanced summary of what was done and 
what was found [Pg. 2] 
Introduction   
Background/rationale 2 Explain the scientific background and rationale 
for the investigation being reported [Pg. 3] 
Objectives 3 State specific objectives, including any pre-
specified hypotheses [Pg. 3] 
Methods   
Study design 4 Present key elements of study design early in 
paper [Pg. 3-4] 
Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, exposure, 
follow-up, and data collection [Pg. 3-4] 
Participants 6 (a) Cohort study: give the eligibility criteria, 
Prescribing	PrEP:	A	Guide	to	Oral	HIV	Prophylaxis	|	Alyse	J.	Moses-Lebron		
	
	 46	
and the sources and methods of selection 
of participants.  Describe methods of 
follow-up [Pg. 4] 
Case-Control Study:  Give the eligibility 
criteria, and the sources and methods of 
case ascertainment and control selection.  
Give the rationale for the choice of cases 
and controls  
Cross-Sectional study: Give the eligibility 
criteria, and the sources and methods of 
selection of participants 
(b) Cohort Study: For matched studies, give 
matching criteria and the number of 
controls per case [pg.4] 
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers.  Give diagnostic criteria, if applicable 
[Pg. 3-4] 
Data 
Sources/measurement* 
8 For each variable of interest, give sources of data 
and details of methods assessment.  Describe 
comparability of assessment methods if there is 
more than one group [Pg. 4] 
Bias 9 Describe any efforts to address potential sources 
of bias [Pg. 4] 
Study Size 10 Explain how the study size was arrived at [Pg.3-
4] 
Quantitative variables 11 Explain how quantitative variables were handled 
in the analyses.  If applicable, describe which 
groupings were chosen and why [not present] 
Statistical Methods 12 (a) Describe all statistical methods, including 
those used to control for confounding [Pg. 
4-5] 
(b) Describe any methods used to examine 
subgroups and interactions [Pg. 5] 
(c) Explain how missing data were addressed 
[Pg. 5] 
(d) Cohort study:  If applicable, explain how 
loss to follow up was addressed [Pg. 5] 
Case-Controlled study: If applicable, 
explain how matching cases and controls 
was addressed 
Cross-sectional study: If applicable, 
describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analysis [Pg. 7] 
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Results   
Participants 13* (a) Report the numbers of individuals at each 
stage of the study- e.g. numbers 
potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, 
completing follow-up and analyzed [Pg. 5-
7] 
(b) Give reasons for nonparticipation at each 
stage [Pg. 7] 
(c) Consider use of a flow diagram [not 
present] 
Descriptive Data 14* (a) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
information on exposures and potential 
confounders [Pg. 5-7] 
(b) Indicate the number of participants with 
missing data for each variable of interest 
[not present] 
(c) Cohort study:  Summarize follow-up time- 
e.g. average and total amount [Pg. 5-6] 
Outcome Data 15* Cohort study: Report numbers of outcome events 
or summary measures over time [Pg.16-17] 
Case control study: Report numbers in each 
exposure category or summary measures of 
exposure  
Cross-sectional study: Report numbers of 
outcome events or summary measures 
Main Results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g. 95% CI).  Make 
clear which confounders were adjusted for 
and why they were included [Pg.5-7] 
(b) Report category boundaries when 
continuous variables were analyzed [not 
present] 
(c) If Relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period  
Other Analyses 17 Report other analyses done- e.g. analyses of 
subgroups and interactions and sensitivity 
analyses [Pg. 7] 
Discussion   
Key results 18 Summarize key results with reference to study 
objectives [Pg. 8] 
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Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or imprecision.  
Discuss both direction and magnitude of any 
potential bias [Pg. 9] 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence [Pg. 9] 
Generalizability 21 Discuss the generalizability (external validity) of 
the study results. [Pg. 9] 
Other Information   
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, of 
the original study on which the present article is 
based. [Pg. 2] 
 
Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral 
Tenofovir for HIV Preexposure Prophylaxis  by Mirembe et al 
STROBE Score: 19 
 
Title and Abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract [not present] 
(b) Provide in the abstract an informative and 
balanced summary of what was done and 
what was found [not present] 
Introduction   
Background/rationale 2 Explain the scientific background and rationale 
for the investigation being reported [Pg. 287-288] 
Objectives 3 State specific objectives, including any pre-
specified hypotheses [Pg. 288] 
Methods   
Study design 4 Present key elements of study design early in 
paper [Pg. 288] 
Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, exposure, 
follow-up, and data collection [Pg. 288] 
Participants 6 (a) Cohort study: give the eligibility criteria, 
and the sources and methods of selection 
of participants.  Describe methods of 
follow-up [Pg. 288] 
Case-Control Study:  Give the eligibility 
criteria, and the sources and methods of 
case ascertainment and control selection.  
Give the rationale for the choice of cases 
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and controls  
Cross-Sectional study: Give the eligibility 
criteria, and the sources and methods of 
selection of participants 
(b) Cohort Study: For matched studies, give 
matching criteria and the number of 
controls per case  
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers.  Give diagnostic criteria, if applicable 
[Pg. 288] 
Data 
Sources/measurement* 
8 For each variable of interest, give sources of data 
and details of methods assessment.  Describe 
comparability of assessment methods if there is 
more than one group [Pg. 288] 
Bias 9 Describe any efforts to address potential sources 
of bias [Pg. 288] 
Study Size 10 Explain how the study size was arrived at [Pg. 
288] 
Quantitative variables 11 Explain how quantitative variables were handled 
in the analyses.  If applicable, describe which 
groupings were chosen and why [Pg. 288] 
Statistical Methods 12 (a) Describe all statistical methods, including 
those used to control for confounding [Pg. 
288-289] 
(b) Describe any methods used to examine 
subgroups and interactions [Pg. 289] 
(c) Explain how missing data were addressed 
[Pg. 289] 
(d) Cohort study:  If applicable, explain how 
loss to follow up was addressed [Pg. 289] 
Case-Controlled study: If applicable, 
explain how matching cases and controls 
was addressed 
Cross-sectional study: If applicable, 
describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analysis [not 
present] 
Results   
Participants 13* (a) Report the numbers of individuals at each 
stage of the study- e.g. numbers 
potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, 
completing follow-up and analyzed [Pg. 
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289] 
(b) Give reasons for nonparticipation at each 
stage [Pg. 289] 
(c) Consider use of a flow diagram [Pg. 289] 
Descriptive Data 14* (a) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
information on exposures and potential 
confounders [Pg. 290] 
(b) Indicate the number of participants with 
missing data for each variable of interest 
[not present] 
(c) Cohort study:  Summarize follow-up time- 
e.g. average and total amount [Pg. 292] 
Outcome Data 15* Cohort study: Report numbers of outcome events 
or summary measures over time [Pg.289-292] 
Case control study: Report numbers in each 
exposure category or summary measures of 
exposure  
Cross-sectional study: Report numbers of 
outcome events or summary measures 
Main Results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g. 95% CI).  Make 
clear which confounders were adjusted for 
and why they were included [Pg.290] 
(b) Report category boundaries when 
continuous variables were analyzed [Pg. 
290] 
(c) If Relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period  
Other Analyses 17 Report other analyses done- e.g. analyses of 
subgroups and interactions and sensitivity 
analyses [Pg. 290 and 292] 
Discussion   
Key results 18 Summarize key results with reference to study 
objectives [Pg. 292-293] 
Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or imprecision.  
Discuss both direction and magnitude of any 
potential bias [Pg. 293] 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence [Pg. 293] 
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Generalizability 21 Discuss the generalizability (external validity) of 
the study results. [Pg. 293] 
Other Information   
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, of 
the original study on which the present article is 
based. [Pg. 288] 
 
 
Bone Mineral Density Changes Among HIV-Uninfected Young Adults in a Randomised Trial of 
Pre-Exposure Prophylaxis with Tenofovir-Emtricitabine or Placebo in Botswana  by 
Kasonde et al 
STROBE Score: 22 
 
Title and Abstract 1 (c) Indicate the study’s design with a 
commonly used term in the title or the 
abstract [Pg. 1] 
(d) Provide in the abstract an informative and 
balanced summary of what was done and 
what was found [Pg. 1] 
Introduction   
Background/rationale 2 Explain the scientific background and rationale 
for the investigation being reported [Pg. 1-3] 
Objectives 3 State specific objectives, including any pre-
specified hypotheses [Pg. 1-3] 
Methods   
Study design 4 Present key elements of study design early in 
paper [Pg. 3] 
Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, exposure, 
follow-up, and data collection [Pg. 3] 
Participants 6 (c) Cohort study: give the eligibility criteria, 
and the sources and methods of selection 
of participants.  Describe methods of 
follow-up [Pg. 3] 
Case-Control Study:  Give the eligibility 
criteria, and the sources and methods of 
case ascertainment and control selection.  
Give the rationale for the choice of cases 
and controls  
Cross-Sectional study: Give the eligibility 
criteria, and the sources and methods of 
selection of participants 
(d) Cohort Study: For matched studies, give 
matching criteria and the number of 
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controls per case  
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers.  Give diagnostic criteria, if applicable 
[Pg. 3] 
Data 
Sources/measurement* 
8 For each variable of interest, give sources of data 
and details of methods assessment.  Describe 
comparability of assessment methods if there is 
more than one group [Pg. 3-4] 
Bias 9 Describe any efforts to address potential sources 
of bias [not present] 
Study Size 10 Explain how the study size was arrived at [Pg. 3-
4] 
Quantitative variables 11 Explain how quantitative variables were handled 
in the analyses.  If applicable, describe which 
groupings were chosen and why [Pg. 3-4] 
Statistical Methods 12 (f) Describe all statistical methods, including 
those used to control for confounding [Pg. 
3-4] 
(g) Describe any methods used to examine 
subgroups and interactions [Pg. 5] 
(h) Explain how missing data were addressed 
[Pg. 3-4] 
(i) Cohort study:  If applicable, explain how 
loss to follow up was addressed [Pg. 3-4] 
Case-Controlled study: If applicable, 
explain how matching cases and controls 
was addressed 
Cross-sectional study: If applicable, 
describe analytical methods taking 
account of sampling strategy 
(j) Describe any sensitivity analysis [Pg. 5] 
Results   
Participants 13* (d) Report the numbers of individuals at each 
stage of the study- e.g. numbers 
potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, 
completing follow-up and analyzed [Pg. 4] 
(e) Give reasons for nonparticipation at each 
stage [Pg. 289] 
(f) Consider use of a flow diagram [Pg. 2] 
Descriptive Data 14* (d) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
information on exposures and potential 
confounders [Pg. 5-6] 
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(e) Indicate the number of participants with 
missing data for each variable of interest 
[Pg. 2] 
(f) Cohort study:  Summarize follow-up time- 
e.g. average and total amount [Pg.5] 
Outcome Data 15* Cohort study: Report numbers of outcome events 
or summary measures over time [Pg.5-7] 
Case control study: Report numbers in each 
exposure category or summary measures of 
exposure  
Cross-sectional study: Report numbers of 
outcome events or summary measures 
Main Results 16 (d) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g. 95% CI).  Make 
clear which confounders were adjusted for 
and why they were included [Pg.6] 
(e) Report category boundaries when 
continuous variables were analyzed [Pg. 
6] 
(f) If Relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period  
Other Analyses 17 Report other analyses done- e.g. analyses of 
subgroups and interactions and sensitivity 
analyses [Pg. 5-7] 
Discussion   
Key results 18 Summarize key results with reference to study 
objectives [Pg. 7] 
Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or imprecision.  
Discuss both direction and magnitude of any 
potential bias [Pg. 8] 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence [Pg. 8] 
Generalizability 21 Discuss the generalizability (external validity) of 
the study results. [Pg.9] 
Other Information   
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, of 
the original study on which the present article is 
based. [Pg. 1] 
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Appendix B SORT Analysis 
SORT Criteria 
 
Study quality Diagnosis Treatment/Prevention/Screening Prognosis  
Level 1: good 
quality patient 
oriented 
evidence 
Validated 
clinical decision 
rule, SR/Meta-
analysis of high 
quality studies 
High- quality 
diagnostic 
cohort study 
SR/meta-analysis of RCTs with 
consistent findings 
High-quality individual RCT 
All-or- none studies 
SR/Meta-
analysis of 
good-quality 
cohort studies 
Prospective 
cohort study 
with good 
follow-up 
 
Level 2: limited 
quality patient 
oriented 
evidence 
   
Level 3: other evidence Consensus guidelines, extrapolations from bench 
research, usual practice, opinion, disease oriented 
evidence (intermediate or physiologic outcomes 
only, or case series for studies of diagnosis, 
treatment, prevention, or screening 
Strength of Recommendation:  
A: Recommendation based on consistent and good-quality patient-oriented evidence 
B: Recommendation based on inconsistent or limited-quality patient-oriented evidence 
C: Recommendation based on consensus, usual practice, opinion, disease-oriented evidence, 
or case series for studies of diagnosis, treatment, prevention, or screening 
 
HIV and Bone Complications: Understudied Populations and New Management Strategies by 
Yin and Brown 
SORT Score: A 
 
HIV prevention trial design in an era of effective pre-exposure prophylaxis by Cutrell et al 
SORT Score: A 
 
Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns by Tetteh et al 
SORT Score: A  
 
Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective by Conniff 
SORT Score: C 
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Appendix C Grade Analysis 
Grade Analysis 
 
Preexposure Prophylaxis for HIV Infection among African Women by Damme et al 
GRADE SCORE: 5/7 
 
Type of 
evidence 
Quality Consistency  Directness Effect Size 
RCT (+4) No Problem 
(0)  
Evidence of Dose 
response/inconsistency 
explained by dose 
response (+1) 
Problem with 
adherence (-
1) 
Not all effect 
sizes >2 or 
<0.5 and 
significant, or 
if OR/RR/HR 
not significant 
 
 
 
